Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-3

  Nishio, Nobuhiro ^a   Dotti, Gianpietro ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chimeric antigen receptor; GD2 antigen; IL 15; Oncolytic virus; RANTES

Indexed keywords

CD137 ANTIGEN; CD19 ANTIBODY; CD28 ANTIGEN; CHEMOKINE RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; INTERLEUKIN 15; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; RANTES; T LYMPHOCYTE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL EXPANSION; CELL GROWTH; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOPATHOGENIC EFFECT; DNA MODIFICATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA CELL; LYMPH NODE; MEASLES VIRUS; MESOTHELIOMA; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VACCINIA VIRUS;

EID: 84954548519     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21505594.2014.988098     Document Type: Article

References (10)

1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
2. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-6; PMID:21540550; http://dx.doi.org/10.1172/JCI46110
3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
4. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535-46; PMID:19451549; http://dx.doi.org/10.1182/blood-2009-03-211714
5. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257:107-26; PMID:24329793; http://dx.doi.org/10.1111/imr.12131
6. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res 2014; 74:5195-205; PMID:25060519; http://dx.doi.org/10.1158/0008-5472.CAN-14-0697
7. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5:965-76; PMID:16294217; http://dx.doi.org/10.1038/nrc1750
8. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-70; PMID:18978797; http://dx.doi.org/10.1038/nm.1882
9. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloom- ston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/nm.3089
10. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O’Connor MK, Kyle RA, Leung N, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89:926-33; PMID:24835528; http://dx.doi.org/10.1016/j.mayocp.2014.04.003